{
    "clinical_study": {
        "@rank": "154661", 
        "acronym": "EFOMS", 
        "arm_group": [
            {
                "arm_group_label": "Fish oil", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the present work was to evaluate the efficacy of fish oil supplementation on\n      serum proinflammatory cytokines levels, oxidative stress markers and disease progression in\n      MS."
        }, 
        "brief_title": "Efficacy of Fish Oil in Multiple Sclerosis", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Relapsing- Remitting Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "detailed_description": {
            "textblock": "Current research findings suggest that Omega-3 polyunsaturated fatty acids (PUFA) such as\n      eicosahexanoic acid (EPA) and docosahexaenoic acid (DHA) contained in fish oil may have\n      anti-inflammatory, antioxidant and neuroprotective effects. The aim of the present work was\n      to evaluate the efficacy of fish oil supplementation on serum proinflammatory cytokines\n      levels, oxidative stress markers and disease progression in MS. 50 patients with\n      relapsing-remitting MS were enrolled. The experimental group received orally 4 g/day of fish\n      oil for 12 months. The primary outcome was serum TNF\u03b1 levels; Secondary outcomes were IL-1\u03b2,\n      IL-6, nitric oxide catabolites, lipoperoxides, progression on the expanded disability status\n      scale (EDSS) and annualized relapses rate (ARR)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients had clinically definite and magnetic resonance image supported MS\n\n          -  Had at least one relapse in the year before entry into the study\n\n          -  EDSS score of 0-5\n\n          -  Treated with subcutaneous 250 \u03bcg interferon beta-1b (Betaseron, Bayer)\n\n        Exclusion Criteria:\n\n          -  they were taking another supplement\n\n          -  had progressive forms of MS\n\n          -  had history of severe depression\n\n          -  had history of acute liver or renal dysfunction\n\n          -  had history of tobacco, drug or alcohol abuse\n\n          -  had intolerance, contraindication or allergy to fish oil"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842191", 
            "org_study_id": "FOMS"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fish oil", 
                "description": "Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.", 
                "intervention_name": "Fish Oil", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "PUFAS", 
                    "Omega 3"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Control"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "R-R MS", 
        "lastchanged_date": "May 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Guadalajara", 
                    "country": "Mexico", 
                    "state": "Jalisco", 
                    "zip": "44340"
                }, 
                "name": "IMSS, Specialties Hospital, Neurology Departament"
            }
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Fish Oil on Serum TNF\u03b1, IL-1\u03b2, IL-6, Oxidative Stress Markers in Multiple Sclerosis Treated With Interferon Beta 1-b", 
        "other_outcome": {
            "description": "EDSS and ARR at baseline, 6 months and 12 months", 
            "measure": "Expanded Disability Status Scale (EDSS) and Annualized rate of relapses (ARR)", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "overall_official": {
            "affiliation": "Social Security Mexican Institute", 
            "last_name": "Genaro G Ortiz, phD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Mexico: Coordinaci\u00f3n de Investigaci\u00f3n en Salud", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Serum TNF alpha levels, at baseline, 3, 6, 9 and 12 months.", 
            "measure": "TNF alpha", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "reference": {
            "PMID": "19242067", 
            "citation": "Ortiz GG, Mac\u00edas-Islas MA, Pacheco-Mois\u00e9s FP, Cruz-Ramos JA, Sustersik S, Barba EA, Aguayo A. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers. 2009;26(1):35-9. doi: 10.3233/DMA-2009-0602."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842191"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Coordinaci\u00f3n de Investigaci\u00f3n en Salud, Mexico", 
            "investigator_full_name": "Genaro Gabriel Ortiz", 
            "investigator_title": "Investigador titular D", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Serum IL-1 beta, IL-6, Lipoperoxides, nitric oxide levels at baseline, 3, 6, 9 and 12 months.", 
            "measure": "IL-1 beta, IL-6, Lipoperoxides, nitric oxide", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "source": "Coordinaci\u00f3n de Investigaci\u00f3n en Salud, Mexico", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Coordinaci\u00f3n de Investigaci\u00f3n en Salud, Mexico", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}